Frazier Life Sciences Management, L.P. 13F: Quarter-over-Quarter Portfolio Changes
Frazier Life Sciences Management, L.P. reported a disclosed portfolio value of approximately $4.6 billion in its latest SEC Form 13F-HR filing for Q2 2026, up 18.2% quarter on quarter. Over the quarter, the fund initiated 6 new positions, bought more shares in 8 holdings, trimmed 2 holdings, and exited 3 positions.
Frazier Life Sciences Management, L.P.'s top buy was a new stake in Parabilis Medicines INC (PBLS) , equal to 1.1% of the disclosed portfolio. Its top sell was Bridgebio Pharma INC (BBIO) . The fund sold 55.1% of its previously reported shares, reducing the position's portfolio weight by 4.1 percentage points.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| PARABILIS MEDICINES INC | PBLS | 1.1% | Holders → |
| ACHIEVE LIFE SCIENCE INC | ACHV | 1.1% | Holders → |
| DESIGN THERAPEUTICS INC | DSGN | 0.6% | Holders → |
| SHATTUCK LABS INC | STTK | 0.6% | Holders → |
| KAILERA THERAPEUTICS INC | KLRA | 0.5% | Holders → |
| RELAY THERAPEUTICS INC | RLAY | 0.4% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| ALLOGENE THERAPEUTICS INC | ALLO | +0.8% | +491.2% | Holders → |
| ASCENDIS PHARMA A/S | SYN_04351P101 | +0.5% | +68.9% | Holders → |
| AURA BIOSCIENCES INC | AURA | +0.2% | +39.2% | Holders → |
| MANNKIND CORP | MNKD | +0.2% | +11.9% | Holders → |
| MAZE THERAPEUTICS INC | MAZE | +-0.2% | +10.2% | History → |
| LEXEO THERAPEUTICS INC | LXEO | +-0.2% | +9.0% | Holders → |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | +-0.6% | +6.8% | History → |
| ERASCA INC | ERAS | +-0.3% | +1.2% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC | BBIO | -4.1% | 55.1% | Holders → |
| TREVI THERAPEUTICS INC | TRVI | 1.0% | 0.0% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| KALVISTA PHARMACEUTICALS | KALV | 2.6% |
| REVOLUTION MEDICINES INC | RVMD | 1.7% |
| AGIOS PHARMACEUTICALS INC | AGIO | 1.1% |
Net Portfolio Value ChangeQ2 2026
- $3.9BPrior quarter
- $4.6BCurrent quarter
- +$0.7BNet delta
- +18.2%% change
Methodology & FAQ
How Frazier Life Sciences Management, L.P. Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Frazier Life Sciences Management, L.P.: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Frazier Life Sciences Management, L.P. buy in Q2 2026?
In Q2 2026, Frazier Life Sciences Management, L.P. initiated 6 new positions (PARABILIS MEDICINES INC (PBLS), ACHIEVE LIFE SCIENCE INC (ACHV), DESIGN THERAPEUTICS INC (DSGN), SHATTUCK LABS INC (STTK), KAILERA THERAPEUTICS INC (KLRA), RELAY THERAPEUTICS INC (RLAY)); bought more shares of ALLOGENE THERAPEUTICS INC (ALLO), ASCENDIS PHARMA A/S (SYN_04351P101), AURA BIOSCIENCES INC (AURA), MANNKIND CORP (MNKD), MAZE THERAPEUTICS INC (MAZE) (the largest 5 of 8 adds).
What stocks did Frazier Life Sciences Management, L.P. sell in Q2 2026?
In Q2 2026, Frazier Life Sciences Management, L.P. fully sold 3 positions (KALVISTA PHARMACEUTICALS (KALV), REVOLUTION MEDICINES INC (RVMD), AGIOS PHARMACEUTICALS INC (AGIO)); reduced holdings in BRIDGEBIO PHARMA INC (BBIO), TREVI THERAPEUTICS INC (TRVI).
Which positions did Frazier Life Sciences Management, L.P. initiate in Q2 2026?
Frazier Life Sciences Management, L.P. established 6 new positions in Q2 2026: PARABILIS MEDICINES INC (PBLS, 1.1%), ACHIEVE LIFE SCIENCE INC (ACHV, 1.1%), DESIGN THERAPEUTICS INC (DSGN, 0.6%), SHATTUCK LABS INC (STTK, 0.6%), KAILERA THERAPEUTICS INC (KLRA, 0.5%), RELAY THERAPEUTICS INC (RLAY, 0.4%).
Which existing positions saw the largest allocation increases for Frazier Life Sciences Management, L.P. in Q2 2026?
Of 8 existing positions with share-count increases in Q2 2026, the largest were: ALLOGENE THERAPEUTICS INC (ALLO, +0.8% weight, +491.2% shares), ASCENDIS PHARMA A/S (SYN_04351P101, +0.5% weight, +68.9% shares), AURA BIOSCIENCES INC (AURA, +0.2% weight, +39.2% shares), MANNKIND CORP (MNKD, +0.2% weight, +11.9% shares), MAZE THERAPEUTICS INC (MAZE, +-0.2% weight, +10.2% shares), LEXEO THERAPEUTICS INC (LXEO, +-0.2% weight, +9.0% shares), NEWAMSTERDAM PHARMA COMPANY (NAMS, +-0.6% weight, +6.8% shares), ERASCA INC (ERAS, +-0.3% weight, +1.2% shares).
Which positions did Frazier Life Sciences Management, L.P. fully exit in Q2 2026?
Frazier Life Sciences Management, L.P. fully exited 3 positions in Q2 2026: KALVISTA PHARMACEUTICALS (KALV, last-reported weight 2.6%), REVOLUTION MEDICINES INC (RVMD, last-reported weight 1.7%), AGIOS PHARMACEUTICALS INC (AGIO, last-reported weight 1.1%).
Which existing positions saw the largest allocation reductions for Frazier Life Sciences Management, L.P. in Q2 2026?
Of 2 existing positions with share-count reductions in Q2 2026, the largest were: BRIDGEBIO PHARMA INC (BBIO, -4.1% weight, -55.1% shares), TREVI THERAPEUTICS INC (TRVI, 1.0% weight, -0.0% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.